J&J(JNJ)
Search documents
Stock Market Today, Jan. 21: U.S. stocks jump after President Trump relaxes Greenland threats in Davos
Yahoo Finance· 2026-01-21 11:58
Market Overview - The U.S. stock market experienced significant declines, with over 70.7% of U.S. issues falling on Tuesday, while only 26.4% advanced [2] - The Nasdaq Composite and S&P 500 dropped by 2.39% and 2.06% respectively, with the Dow and Russell 2000 also showing losses of 1.76% and 1.20% [3] Earnings Reports - Major earnings reports expected today include Johnson & Johnson, Charles Schwab, and Prologis, with a focus on regional banks reporting in both premarket and aftermarket sessions [5] - The S&P Regional Bank ETF ($KRE) is anticipated to be particularly responsive to these reports, having risen over 14% since its lows in November 2025 [6]
强生第四季度销售额245.6亿美元 高于预期
Ge Long Hui A P P· 2026-01-21 11:39
格隆汇1月21日|强生(JNJ.US):第四季度销售额为245.6亿美元,高于预期的241.5亿美元。预计2026财 年运营销售额为995亿至1005亿美元,高于预估的989亿美元。 ...
强生(JNJ.N)预计2026财年运营销售额为995亿至1005亿美元,高于预估的989亿美元。
Jin Rong Jie· 2026-01-21 11:39
本文源自:金融界AI电报 强生(JNJ.N)预计2026财年运营销售额为995亿至1005亿美元,高于预估的989亿美元。 ...
Johnson & Johnson forecasts 2026 profit above Wall Street estimates
Reuters· 2026-01-21 11:23
Johnson & Johnson on Wednesday forecast 2026 sales and profit ahead of Wall Street estimates, even when including a hit of "hundreds of millions of dollars" from the drug pricing deal it signed with... ...
Johnson & Johnson Non-GAAP EPS of $2.46 in-line, revenue of $24.6B beats by $440M (JNJ:NYSE)
Seeking Alpha· 2026-01-21 11:21
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...
J&J's Sales and Profit Rise on Strong Cancer and Autoimmune Drug Sales
WSJ· 2026-01-21 11:20
The healthcare company's forecast for 2026 tops Wall Street's expectations. ...
Johnson & Johnson reports Q4 and Full-Year 2025 results
Businesswire· 2026-01-21 11:20
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full-year 2025. "2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history,†said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "Last year kicked off a new era of accelerated growth, driven by medical innovation that is transforming lives in our six key businesses: Oncology, Immunology, Neuros. ...
Stock Market Today: Dow Jones, S&P 500 Futures Recover As Focus Turns To Trump's Davos Address—Johnson & Johnson, Intel, GameStop In Focus - SPDR S&P 500 (ARCA:SPY)
Benzinga· 2026-01-21 10:16
U.S. stock futures rose on Wednesday following Tuesday’s sharp sell-off. Futures of major benchmark indices were higher.On Tuesday, the S&P 500 index recorded its worst session since October 2025, dipping more than 2% during the session as risk-off sentiment intensified following President Donald Trump's aggressive new trade stance toward Europe. Trump threatened several European countries with additional tariffs starting Feb. 1 if negotiations over Greenland control fail, with duties potentially rising to ...
一款术前模拟 App,强生想补哪一环?
思宇MedTech· 2026-01-21 09:00
2026 年 1 月, Johnson & Johnson MedTech 宣布,在美国市场正式推出 Arbrea Breast Simulator Surgeon App for Mentor 。该产品是一款面向整形外科医生的 移动端数字化咨询工具 ,可运行于平板和智能手机, 用于乳房手术(尤其是隆乳手术)的术前沟通与方案展示。 从定位上看,该应用并非手术器械或术中系统,而是服务于 医患沟通与决策前端 的数字工具,目标在于提 升咨询阶段的可视化程度与沟通效率。 3. 实时辅助医生与患者讨论 医生可在咨询过程中动态展示不同方案的潜在效果,支持更结构化的方案对比与讨论,而非单向讲解。 从 技术属性上看,该产品属于 数字健康与三维可视化软件 ,并未涉及术中导航或治疗决策。 # 了解 A rbrea ( 一 ) 功能与技术特点拆解 根据强生 MedTech 的公开说明,Arbrea 应用的核心功能集中在以下几个方面: 1. 快速生成个性化 3D 模拟结果 应用可在约 60 秒内 生成患者个性化的三维模拟效果,用于展示不同隆乳方案可能带来的外观变化。 2. 替代传统"物理尺码 + 图片库"的沟通方式 强生指出,目前多 ...
JNJ Earnings Preview: Solid Q4 Expected With Revenue Growth Above 5% in Sight
Investing· 2026-01-21 07:38
Market Analysis by covering: S&P 500, Johnson & Johnson. Read 's Market Analysis on Investing.com ...